Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

COEP

Coeptis Therapeutics Holdings Inc

Nov 26 • 04:00PM ET

18.80

+1.16 6.58 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN PFE MRNA BNTX JNJ VRTX AZN AMGN LLY

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.95	Insider Own	15.45%	Shs Outstand	5.16M	Perf Week	17.79%
Market Cap	100.39M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.51M	Perf Month	23.40%
Enterprise Value	95.89M	PEG	-	EPS next Q	-	Inst Own	2.71%	Short Float	2.58%	Perf Quarter	48.50%
Income	-12.34M	P/S	200.78	EPS this Y	-	Inst Trans	-0.39%	Short Ratio	2.39	Perf Half Y	97.89%
Sales	0.50M	P/B	7.78	EPS next Y	-	ROA	-90.30%	Short Interest	0.12M	Perf YTD	241.82%
Book/sh	2.42	P/C	18.83	EPS next 5Y	-	ROE	-127.31%	52W High	19.19 -2.03%	Perf Year	383.04%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	38.79% -322.46%	ROIC	-97.84%	52W Low	2.31 713.85%	Perf 3Y	-58.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-592.22%	Volatility	9.86% 8.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	191.78	EPS Y/Y TTM	37.81%	Oper. Margin	-2638.23%	ATR (14)	1.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.21	Sales Y/Y TTM	-	Profit Margin	-2463.79%	RSI (14)	70.46	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.21	EPS Q/Q	37.18%	SMA20	21.16%	Beta	-0.53	Target Price	80.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	19.66%	Rel Volume	6.14	Prev Close	17.64
Employees	7	LT Debt/Eq	0.01	Earnings	-	SMA200	61.28%	Avg Volume	48.67K	Price	18.80
IPO	Dec 17, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	298,759	Change	6.58%

Sep-23-25 08:00AM	Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating (GlobeNewswire) +13.41%
Jul-22-25 08:36AM	Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd (GlobeNewswire)
Jun-26-25 08:34AM	Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared (GlobeNewswire)
May-28-25 08:28AM	Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology (GlobeNewswire)
May-12-25 08:20AM	NUBURU Files $100M SEC Registration Statement to Enhance Capital Flexibility for Completion of Defense Acquisition and Blue Laser Technology Revitalization Targeting a $500B Defense Market (Business Wire)
08:33AM	Loading…
Apr-25-25 08:33AM	Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement (GlobeNewswire) -38.25%
Apr-17-25 08:38AM	COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology (GlobeNewswire) +7.82%
Apr-15-25 08:33AM	NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives (Business Wire)
Mar-11-25 08:34AM	Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline (GlobeNewswire)
Mar-07-25 08:37AM	COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan (GlobeNewswire)
Mar-06-25 08:00AM	NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan (Business Wire) -5.09%
Feb-20-25 09:00AM	COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network (GlobeNewswire) -16.44%
07:27AM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-19-25 04:00PM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-13-25 08:39AM	COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups (GlobeNewswire)
08:08AM	Loading…
Feb-06-25 08:08AM	COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration (PR Newswire)
Jan-30-25 08:27AM	Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation (PR Newswire)
Jan-23-25 08:09AM	Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation (PR Newswire) -9.81%
Jan-22-25 08:00AM	Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) (PR Newswire) +13.56%
Jan-07-25 08:00AM	Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform (PR Newswire)
Dec-27-24 08:15AM	Coeptis Therapeutics Announces Reverse Stock Split (PR Newswire) -13.65%
Dec-26-24 08:15AM	Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies (PR Newswire) +48.59%
Dec-12-24 08:00AM	Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies (PR Newswire)
Dec-03-24 08:15AM	Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries (PR Newswire) +17.51%
Nov-07-24 08:07AM	Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development (PR Newswire)
Oct-24-24 08:07AM	Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use (PR Newswire) -6.64%
Oct-15-24 08:07AM	Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy (PR Newswire)
Sep-19-24 07:07AM	Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire) +5.47%
Sep-05-24 08:07AM	Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders (PR Newswire) -5.66%
Aug-16-24 08:52PM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024 (InvestorPlace) +5.15%
08:47AM	Loading…
Jun-20-24 08:47AM	Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering (PR Newswire) -8.81%
May-30-24 08:47AM	Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting (PR Newswire)
May-13-24 09:53AM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.07%
May-08-24 08:47AM	Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 (PR Newswire)
May-02-24 08:47AM	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (PR Newswire) +8.77%
Apr-02-24 08:47AM	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award (PR Newswire) +6.68%
Feb-26-24 09:00AM	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PR Newswire) +9.89%
Feb-07-24 07:30AM	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections (PR Newswire)
Jan-04-24 07:30AM	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 (PR Newswire) -10.71%
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) -7.02%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire) -5.00%
Dec-04-23 07:30AM	Coeptis Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Oct-31-23 09:01AM	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 (PR Newswire) -9.74%
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-24-23 08:30AM	Coeptis Therapeutics Announces $2 Million Private Placement (PR Newswire)
Oct-11-23 07:30AM	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology (PR Newswire)
Oct-09-23 09:15AM	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies (PR Newswire)
Oct-04-23 07:30AM	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (PR Newswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Sep-27-23 07:30AM	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa (PR Newswire) +10.31%
Sep-14-23 07:30AM	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection (PR Newswire)
Sep-11-23 07:30AM	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment (PR Newswire) -5.29%
Aug-30-23 01:00PM	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer (PR Newswire)
Aug-17-23 07:30AM	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics (PR Newswire)
Aug-01-23 08:00AM	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic (PR Newswire)
Jun-16-23 04:00PM	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering (PR Newswire) -5.59%
Jun-14-23 09:28AM	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering (PR Newswire) +6.06%
Jun-09-23 07:00AM	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market (PR Newswire)
May-17-23 08:30AM	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer (PR Newswire)
May-10-23 03:00PM	Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications (PR Newswire)
Apr-18-23 07:30AM	Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics (PR Newswire) +9.16%
Mar-29-23 09:45AM	Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies (PR Newswire)
Mar-21-23 07:00AM	Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine (PR Newswire)
Feb-07-23 08:00AM	Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling (PR Newswire)
Jan-31-23 07:30AM	Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program (PR Newswire) +12.73%
Nov-22-22 07:00AM	Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program (PR Newswire) -6.17%
Nov-15-22 07:00AM	Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell (PR Newswire)
Nov-08-22 07:00AM	Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast (PR Newswire) -17.13%
Nov-02-22 07:00AM	Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments (PR Newswire) -8.81%
Sep-21-22 07:00AM	Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology (PR Newswire)
May-17-22 07:00AM	Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors (PR Newswire)
Apr-19-22 07:00AM	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement (PR Newswire)
Apr-13-22 04:05PM	Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod (GlobeNewswire)
07:00AM	Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma (PR Newswire)
Jan-20-22 08:00AM	Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development (PR Newswire)

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yerace Daniel Alexander	Director	Sep 02 '25	Proposed Sale	12.96	5,000	64,800		Sep 02 10:04 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

COEP

Coeptis Therapeutics Holdings Inc

Upgrade your FINVIZ experience